GREEN BAY, WI (Oct. 18, 2022) – TitletownTech, a venture capital firm formed out of a partnership between the Green Bay Packers and Microsoft, is expanding its portfolio with its investment in Stemloop, a Chicago-based biosensor company developing novel technology for applications across environmental monitoring, biomanufacturing, and human health.
The funds will enable Stemloop’s commercial launch of its first product, the µSense™ Lead-in-Water Test, and allow the team to make key investments for rapid manufacturing scale up, as well as key hires in R&D and business development. Stemloop is also investing in its bioinformatics capabilities to enable rapid prototyping of future sensors, engineering custom biosensors for players in the environmental, agricultural, biomanufacturing, and human health spheres.
Stemloop’s µSense™ Lead-in-Water Test repurposes biological mechanisms to create sensors that function outside of a cell to detect lead in drinking water. The 30-minute, binary test, like the lateral flow test kit necessitated by the COVID-19 pandemic, allows anyone to detect lead (>=5 ppb) in the comfort their own home without the delay of traditional laboratory testing.
“We’re delighted to announce our investment in Stemloop,” said TitletownTech Managing Director Jill Enos. “Stemloop’s cell-free biosensor technology has exciting applications across a variety of industries and reflects our commitment to finding innovative solutions to meaningful problems.”
On a mission to unlock biology’s power to sense and respond to the world’s challenges, Stemloop’s scientific co-founding team has published many peer-reviewed biosensor technology articles in top scientific journals, like Nature and ACS Synthetic Biology. Additionally, the team’s work has been featured by Scientific American, Axios, Forbes, and the Daily Beast.
“We’re thrilled to receive this support from TitletownTech to continue expanding our operations,” said Stemloop Founder and CEO Khalid Alam. “Information is at the heart of solving the lead-in-water crisis, and by delivering accurate information at scale, Stemloop’s product provides critical answers. That’s what our biosensor platform is all about – utilizing nature’s sensing superpowers to respond to hard-to-detect challenges.”
Stemloop presented its µSense™ product at Chicago Water Week 2022 and is actively seeking additional commercial partners to pilot the test. For more information, please visit www.Stemloop.com/usense. Test kits are not yet available to the general public.
For more information on TitletownTech, please visit www.TitletownTech.com.
About TitletownTech
Formed in 2019 out of a partnership between the Green Bay Packers and Microsoft, TitletownTech is a Wisconsin-based, seed-stage venture capital firm that invests in bold entrepreneurs solving meaningful problems. Located in Green Bay’s Titletown, TitletownTech’s unique ecosystem convenes engaged investors, in-residence partners, industry advisors, higher education, and a dedicated team to provide founders with support and guidance tailored to their needs. With investments across six verticals: sports, media, & entertainment; digital health; agriculture, water, & the environment; manufacturing & construction; supply chain & logistics; and cross-industry technology, TitletownTech invests across the US, with a focus on the Midwest. For more information, please visit www.TitletownTech.com.
About Stemloop
Stemloop, Inc., "The Biosensor Company," is driven by its mission to unlock biology's power to sense and respond to the world's challenges. Founded in 2019 in Evanston, IL, Stemloop develops novel sensor technology for applications that require high accuracy and large scale in environmental monitoring, biomanufacturing, and human health. Stemloop’s first product, the µSense Lead-in-Water Test, helps inform efforts to get the lead out of America's drinking water, with a commercial launch scheduled for Q4 2022.
Comments